Biolex uses its LEX System and "Plantibodies" technologies for harvesting proteins from Lemna, an aquatic plant, and genetically transforming them into monoclonal antibodies for use in treating human diseases such as hepatitis C. Its lead drug candidate, Locteron, when combined with ribavarin, greatly reduces the viral load of the disease while causing fewer side effects. Its BLX-155 is used to dissolve blood clots; BLX-301 is designated for treating non-Hodgkin's B-cell lymphoma. Chairman Chris Hegal owns just under 25% of the company. Biolex has withdrawn its IPO filing.

Noramco, a subsidiary of healthcare giant Johnson & Johnson, makes active pharmaceutical ingredients used in the medications and medical devices made by Johnson and Johnson subsidiaries (including Ortho-McNeil Pharmaceutical, Janssen, and Ethicon), as well as third parties. The company was founded in 1979 to support the manufacture of Ortho-McNeil's Tylenol with codeine product line. It is one of a very few US companies allowed by the DEA to import such controlled substances as opium for use in painkillers like oxycodone and morphine. Noramco operates two manufacturing facilities in Athens, Georgia, and Wilmington, Delaware.

Quidel Corporation was founded in 1979 and is based in San Diego, California. Quidel Corporation is engaged in the development, manufacturing and marketing of rapid diagnostic solutions for decentralized applications, including professional point-of-care (POC) in infectious diseases, reproductive and women’s health. The Company focuses on POC testing solutions specifically developed for the physician office lab (POL) and acute care markets globally. It sells its products to professionals for use in physician offices, hospitals, clinical laboratories and wellness screening centers. Its POC testing solutions are designed to provide specialized results that meet two value criteria that the Company has branded as Quidel Value Build (QVB). The Company provides rapid POC and other diagnostic tests under brand names, including QuickVue, QuickVue+, QuickVue Advance, Metra, Quidel and MicroVue. The Company markets its products in the United States through a network of national and regional distributors, supported by a direct sales force.

NPS Pharmaceuticals, Inc. company was founded in 1986 and is headquartered in Bedminster, New Jersey. NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of specialty therapeutics for gastrointestinal and endocrine disorders. The company is advancing two late-stage programs to restore or replace biological function, including GATTEX (teduglutide), which is in Phase 3 clinical development for parenteral dependent short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection) that is in Phase 3 clinical development as a hormone therapy for hypoparathyroidism. It complements its internal programs with strategic partnerships with Amgen, GlaxoSmithKline, Kyowa Kirin, and Nycomed.

AstraZeneca was founded in 1992 and is headquartered in London, the United Kingdom. AstraZeneca plc (LSE: AZN) operates independently of Imperial Chemical Industries plc as of June 1, 1993. AstraZeneca plc discovers, develops, manufactures, and markets prescription pharmaceuticals and biological products in the areas of cardiovascular, gastrointestinal, neuroscience, oncology, respiratory and inflammation, and infection worldwide. Its primary products include Arimidex for hormonal breast cancer; Crestor that provides treatment for managing cholesterol levels; Nexium for acid-related diseases; Seroquel, an atypical anti-psychotic therapy for treating schizophrenia and bipolar mania; and Symbicort for the treatment of asthma in patients.AstraZeneca company also engages in the research, development, manufacture, and marketing of medical devices and implants for use in urology, surgery, and odontology. In addition, it develops and manages hospital-based outpatient cancer centers in the United States; and produces individually adapted abutments for dental implants using a patented CAD/CAM method. The company markets its products to primary care and specialist physicians, as well as to other healthcare professionals, governments, and healthcare buying groups through sales and marketing network, local marketing companies, distributors, and local representative offices. It has collaboration agreements with Bristol-Myers Squibb Company; POZEN Inc.; Abbott laboratories; Palatin Technologies, Inc; BioDuro Inc.; Jubilant Organosys Ltd.; Merck & Co. Inc.; Cancer Research Technology Limited; Institute of Cancer Research; Alcon Inc.; Mental Health Research Institute; Targacept, Inc.; and Dako Denmark A/S. AstraZeneca also has a drug discovery and development agreement with PsychoGenics Inc. to identify compounds that are useful for the treatment of certain central nervous system disorders.

Avexa discovers drugs to treat vexing ailments. The pharmaceutical and research company works on the discovery and development of drugs for the treatment of infectious diseases, specifically HIV and antibiotic-resistant strains of bacteria. Avexa has worked on collaborative projects with Victorian College of Pharmacy, The Shanghai Institute of Organic Chemistry, North Carolina State University, and Georgetown University, among other institutions. The company was formed in 2004 when it was spun off from Australian drug discovery and biotechnology development company Amrad. Plans to merge with drugmaker Progen Pharmaceutical were canceled in 2009.

Vetoquinol S.A. was founded in 1933 and is based in Lure, France. Vétoquinol S A engages in the research and development, manufacture, marketing, and sale of medicines and nutraceuticals for animal health. It offers Marbocyl, an antibiotic for various species; Tolfédine and Tolfine anti-inflammatories for minimizing animal pain; and Prilium, an oral daily administration formula for cardiovascular treatment. The company’s products are used for dogs, cats, cattle, and pigs. It sells its products in Europe, North America, Africa, the Middle East, and the Pacific Asia. Vétoquinol S A was formerly known as Laboratoires Biochimiques de l’Est and changed its name to Vetoquinol S.A. in 1962.

Synarc, Inc. provides medical image-analysis, subject-recruitment, and biochemical-marker services to execute clinical trials for life-science industry clients. The company’s services include protocol design, imaging-site selection and training, imaging equipment monitoring, imaging quality assurance, centralized image analysis, centralized biochemical-marker assays, data management, project management, reporting and medical writing, and regulatory consulting and liaison with global agencies. It offers its services in various therapeutic areas, including cardiology, metabolic disorders, neurovascular diseases, neurology, oncology, orthopedics, osteoarthritis, osteoporosis, and rheumatoid arthritis. Synarc also operates clinical research centers in Europe, China, and Brazil. The company, formerly known as Advanced Imaging Research Services, Inc., was founded in 1998 and is based in San Francisco, California with additional offices in the United States, Denmark, France, Germany, Poland, the Czech Republic, Romania, Lithuania, Estonia, Brazil, Hong Kong, and China.

Prolexys Pharmaceuticals wouldn't necessarily characterize proteins as difficult to characterize, especially not if it's using the technology it developed. The biotech research firm's HySpec and HyNet are high-throughput systems for protein expression, purification, and analysis. Prolexys, formerly known as Myriad Proteomics, has also developed its own bioinformatics to put together protein interaction maps from the data generated by HySpec and HyNet. The company has been focusing on cancer research, working with groups such as Columbia University and the Tower Cancer Research Foundation to study advanced solid tumors. Myriad Genetics spun off Prolexys, which was founded in 2001, as a private company in 2003.

Dyadic International, Inc. (Dyadic) is an early-stage biotechnology company. The Company has operations in the United States, the Netherlands and Poland. Dyadic uses its technologies to conduct research and development (R&D) and commercial activities for the discovery, development, manufacture and sale of products and solutions for the bioenergy, industrial enzyme, and biopharmaceutical industries. The Company derives all of its revenues from the licensing of its technologies and the sale of its enzymes. The Company is a holding company that holds all of Dyadic International (USA), Inc. (Dyadic-Florida). Dyadic-Florida owns all of Geneva Investment Holdings Limited, Dyadic Nederland BV, and Dyadic International Sp. z o.o. Dyadic’s R&D activities focus on its fungal strains and associated technologies. In particular, Dyadic uses its Trichoderma and C1 fungal strains in the production of its industrial enzymes.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.